QUANTUM SI™

Corporate Presentation

June 2023

QUANTUM SI™

QuantumSi

Corporate Presentation

June 2023

QuantumSi

Disclaimer

Cautionary Note Regarding Forward-Looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the “Company”) may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s future products and services, or the Company’s plans expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company’s business; the inability to maintain the listing of the Company’s shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the benefits of the Company’s business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development activities; the potential attributes and benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services following commercial launch; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Quantum-Si: The Protein Sequencing Company™

Experienced Team
From life sciences leaders including Illumina, Millipore Sigma, PacBio, and Ion Torrent

192
Employees

Cash runway into 2026
$322M cash at end of Q1

Time Domain Sequencing™
Novel method sequences peptides at the amino acid level in a massively parallel fashion on a semiconductor chip

>1,000
Patents issued & applications pending

Peer-Reviewed Technology
Published in *Science* in October 2022

Platinum™, the world's first next-generation single-molecule protein sequencing platform is now commercially available

$449K in orders in first quarter of commercial launch

Proteomics market opportunity valued at **$75B+**[1]

QuantumSi

1. SVB Leerink Research, "Proteomics: The Next Frontier in Life Science Tools and Diagnostics", September 28, 2021

Quantum-Si: 1Q23 Financial Highlights

$254K revenue
on
$449K orders

48.8%
Gross Margin

$322M
cash at end of 1Q23

Unlocking the Value of the Proteome



Proteins are the main structural and functional components of cells and they are extremely diverse

Protein modifications are real-time indicators of health and disease, making them ideal markers for disease, drug response and health

85% of the **human proteome** is currently undrugged[1], potential for game changing drug development

Next-generation, single-molecule protein sequencing provides an unbiased view of amino acid mutations and post-translational modifications (PTMs) that can be missed by affinity-based methods

1. Chemical & Engineering News, “A Quest to Drug the Undruggable”, June 20, 2018

Large and Growing Market Opportunity

$75B+ Proteomics Market[1]

$8B+ Initial Target Market[2]



1. SVB Leerink Research, "Proteomics: The Next Frontier in Life Science Tools and Diagnostics", September 28, 2021
2. Decibio Consulting Evaluation, June 2020

The Quantum-Si Solution

Sample Prep

CARBON™ (Launch 2H23)

Universal cartridge based sample preparation and automation

Sequencing & Cloud Analysis

PLATINUM™

Massively Parallel, Single Molecule Detection

Reagents & Chips

CONSUMABLES

Library Prep & Protein Sequencing

Disruptive Technology

Accessible Design

Proven Team & Technology

Quantum-Si's Technology: Time Domain Sequencing



Massively parallel analysis on a semiconductor chip



Single molecule sequencing reactions in independent wells



Beyond color with Time Domain Sequencing

Proprietary Amino Acid Recognizers Deliver Industry Leading Proteome Coverage



- World class protein engineering and directed evolution program in-house
- Recognition of up to 15 out of 20 amino acids
- Path to >70% coverage of the human proteome
- Identification of up to 90% of proteins, as well as a greater understanding of protein sequence variation and post-translational modifications (PTMs)
- Working to further increase proteome coverage in 2023

Post-Translational Modifications: See What Others Can't

- **Single-molecule binding kinetics** enables the detection of PTMs without the need to develop new affinity reagents (no *a priori* knowledge is needed)
- ADMA and SDMA have **distinct kinetic signatures** despite having identical mass (these two PTMs are unlikely to be distinguished by mass spec)
- Quantum-Si technology can unlock the ability to study complex disease pathways and discover novel biomarkers



Drug Targets that Modify Proteoforms are Driving M&A Deal Value

- Kinases are drug targets that phosphorylate proteins to generate proteoforms
- $100B in deal value for Kinase inhibitors in the last decade - represents 37% of the total Pharma/Biotech M&A value[1]
- Blockbuster drugs include kinase inhibitors for leukemias (CLL/SLL), melanoma and other cancers

Example for CLL (chronic lymphocytic leukemia):

BTK is a Kinase that activates B-Cell proliferation by phosphorylating a protein (PLCG2)



1. BioPharma Dive, “Meet the protein responsible for nearly $100B in cancer drug deals”, August 16, 2019

Accessible to Any Lab, Anywhere



Proteins → Library Prep → Load Chip → Sequence → Data Analysis

- Benchtop instrument; User installable
- Low capital cost
- Leverages standard laboratory workflow
- Simplified and automated data analysis

Quantum-Si Cloud: Automated Data Analysis

Cloud-based analysis software delivers high quality peptide calls that are automated and easy to interpret

Data from Mass Spectrometry Core Lab



Master	Accession	Description	Contaminant	Coverage [%]	# Peptides	# PSMs	# Unique Peptides	# AAs	MW [kDa]	calc. pI	Score Sequest HT: Sequest HT	# Peptides (by Search Engine): A16 PMI-Byonic	# Peptides (by Search Engine): Sequest HT	|Log Prob| (by Search Engine): PMI-Byonic A16	# Pro
Master Protein	Q49AH0	Cerebral dopamine neurotrophic factor OS=Homo sapiens OX=9606 GN=CDNF PE=1 SV=2	FALSE	76	25	506	15	187	21	7.55	467.45	25	15	202.78	
Master Protein	Q49AH0-2	Isoform 2 of Cerebral dopamine neurotrophic factor OS=Homo sapiens OX=9606 GN=CDNF	FALSE	72	11	140	1	85	9.8	7.8	416.96	1	10	11.13	
Master Protein	P53999	Activated RNA polymerase II transcriptional coactivator p15 OS=Homo sapiens OX=9606 GN=SUB1 PE=1 SV=3	FALSE	29	4	7	4	127	14.4	9.6		4		20	
Master Protein	P16402	Histone H1.3 OS=Homo sapiens OX=9606 GN=H1-3 PE=1 SV=2	FALSE	25	5	13	4	221	22.3	11.02	20.14	5	4	36.15	
Master Protein	P11142	Heat shock cognate 71 kDa protein OS=Homo sapiens OX=9606 GN=HSPA8 PE=1 SV=1	FALSE	22	11	16	11	646	70.9	5.52	12.44	11	4	52.54	
Master Protein	P16401	Histone H1.5 OS=Homo sapiens OX=9606 GN=H1-5 PE=1 SV=3	FALSE	17	3	5	2	226	22.6	10.92	9.58	2	3	14.39	
Master Protein	P67809	Y-box-binding protein 1 OS=Homo sapiens OX=9606 GN=YBX1 PE=1 SV=3	FALSE	16	3	6	3	324	35.9	9.88	10.17	3	2	26.28	
Master Protein	P13645	Keratin, type I cytoskeletal 10 OS=Homo sapiens OX=9606 GN=KRT10 PE=1 SV=6	FALSE	8	3	6	3	584	58.8	5.21	5.88	3	2	15.76	
Master Protein	P61254	60S ribosomal protein L26 OS=Homo sapiens OX=9606 GN=RPL26 PE=1 SV=1	FALSE	8	1	2	1	145	17.2	10.55	2.75	1	1	3.21	
Master Protein	P02765	Alpha-2-HS-glycoprotein OS=Homo sapiens OX=9606 GN=AHSG PE=1 SV=2	FALSE	7	3	6	3	367	39.3	5.72	6.31	3	1	10.08	
Master Protein	Q9H3W5	Leucine-rich repeat neuronal protein 3 OS=Homo sapiens OX=9606 GN=LRRN3 PE=2 SV=1	FALSE	6	5	8	5	708	79.4	7.83	2.6	5	1	17.7	
Master Protein	P02533	Keratin, type I cytoskeletal 14 OS=Homo sapiens OX=9606 GN=KRT14 PE=1 SV=4	FALSE	6	2	3	2	472	51.5	5.16	4.54	2	1	6.26	
Master Protein	P07305	Histone H1.0 OS=Homo sapiens OX=9606 GN=H1-0 PE=1 SV=3	FALSE	5	1	1	1	194	20.9	10.84		1		2.71	
Master Protein	Q8NOW4	Neuroligin-4, X-linked OS=Homo sapiens OX=9606 GN=NLGN4X PE=1 SV=1	FALSE	4	2	2	2	816	91.9	6.21		2		10.98	
Master Protein	P55145	Mesencephalic astrocyte-derived neurotrophic factor OS=Homo sapiens OX=9606 GN=MANF PE=1 SV=3	FALSE	4	1	1	1	182	20.7	8.69		1		4.14	
Master Protein	O15031	Plexin-B2 OS=Homo sapiens OX=9606 GN=PLXNB2 PE=1 SV=3	FALSE	3	3	4	3	1838	205	6.24	4.48	3	1	8.25	
Master Protein	P63267	Actin, gamma-enteric smooth muscle OS=Homo sapiens OX=9606 GN=ACTG2 PE=1 SV=1	FALSE	3	1	2	1	376	41.9	5.48	0	1	1	3.9	
Master Protein	P40926	Malate dehydrogenase, mitochondrial OS=Homo sapiens OX=9606 GN=MDH2 PE=1 SV=3	FALSE	3	1	1	1	338	35.5	8.68	2.71		1	1.07	
Master Protein	81857006	*CON* RecName: Full=Lysyl endopeptidase; AltName: Full=Protease IV; AltName: Full=PvdS-regulated endoprotease; Flag	FALSE	3	1	1	1	462	48.2	6.95	3.48		1		
Master Protein	Q7Z3E5	LisH domain-containing protein ARMC9 OS=Homo sapiens OX=9606 GN=ARMC9 PE=1 SV=3	FALSE	2	2	14	2	818	91.8	6.2		2		5.04	
Master Protein	Q7Z6K1	THAP domain-containing protein 5 OS=Homo sapiens OX=9606 GN=THAP5 PE=1 SV=2	FALSE	2	1	1	1	395	45.4	6.71		1		2.62	
Master Protein	Q14588	Zinc finger protein 234 OS=Homo sapiens OX=9606 GN=ZNF234 PE=2 SV=3	FALSE	2	1	1	1	700	80.5	8.63	2.24		1		
Master Protein	Q13061	Triadin OS=Homo sapiens OX=9606 GN=TRDN PE=1 SV=4	FALSE	1	1	1	1	729	81.5	9.42	1.72		1		

Data from the Quantum-Si Cloud



Quantum-Si is Differentiated from the Competition

	Quantum-Si	Encodia	Nautilus	SomaLogic	Olink
Commercially Available	✓	X	X	✓	✓
Technology	Direct kinetic sequencing	Binding + Degradation with NGS readout	Aptamers/Antibodies	Aptamers	Antibodies
Instrument Cost	$	$$$*	$$$	$$-$$$**	$-$$$**
Run Cost	$	$$-$$$*	$$-$$$	$$-$$$**	$-$$$**
AA Sequencing	✓	Limited	X	X	X
PTM Detection	✓	?	?	Requires PTM specific reagent development	
Automated Data Analysis	✓	?	?	?	?

Note: *NGS instrument required; **NGS instrument optional

Quantum-Si is Leading the Protein Sequencing Revolution

The analog to digital transition creates new market opportunities – we have seen this before

20,000 Genes (Genomics)

1,000,000+ Proteoforms (Proteomics)

Analog

Microarrays

affymetrix

Affinity-based Protein Arrays

somalogic

Olink

Quanterix
The Science of Precision Health

nautilus biotechnology

Digital

DNA Sequencing

A T C G

PacBio

ion torrent

illumina

SINGULAR GENOMICS

Oxford NANOPORE Technologies

Element Biosciences

ULTIMA GENOMICS

Protein Sequencing

R H K D E S T I L M
N Q C G P A V F Y W

QuantumSi

ENCODIA

2023 Commercial Priorities

Build a World-Class Team
Expand team across sales, marketing and service in line with achieving key commercial metrics

Drive Awareness Through Data
Posters/presentations at conferences, peer-review publications, webinars

New Product Launches
Launch Carbon, new analysis tools, expanded proteome coverage



Develop Product Evangelists
New product testing, publications, peer-to-peer collaboration

Accelerate the Purchase Process
Offer a quick turnaround, proof-of-concept testing service

Industry Partnerships
Deliver the most complete end-to-end suite of products for customers

Commercial Highlights from 1Q23

Customer Applications



Expanding Awareness

HUPO HUMAN PROTEOME ORGANIZATION translating the code of life

AACR American Association for Cancer Research FINDING CURES TOGETHER

AIB Research • Technology Communication • Education

Global Sales Funnel



Facilitating Adoption via Proof-of-Concept Testing Service

Customer sends samples and pays a modest fee

Quantum-Si sequences samples

Data is analyzed and reported to customer

Customer purchases Platinum

Proof-of-Concept Results for Major Academic Research Center

Rapid and Accurate Distinction of Variants of the SARS-CoV-2 Virus

Differentiating Alpha via the L452R mutation



Differentiating Omicron via the K417N mutation



Quantum-Si is off to a Strong Start in 2023

Commercialize Platinum, Carbon and 2M Chip

- Platinum launch is on track to internal plan, revenue acceleration in second half; Carbon Beta testing is on track to start in 2Q23, launch 2H23

Lead with Innovation

- Presented scientific posters at US HUPO, AACR, ABRF; Continuing to develop new data analysis tools and expand proteome coverage;

Preserve Financial Strength

- Strong initial gross margins (48.8% in 1Q23); Cash runway into 2026; Continued fiscal discipline

QuantumSi

The Protein Sequencing Company™

Q&A

QuantumSi